Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.65 |
| ▸ | KDR | P35968 | 8/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.65 |
| ▸ | TEK | Q02763 | 2/20 | 0.65 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.65 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | LYN | P07948 | 2/20 | 0.56 |
| ▸ | RET | P07949 | 2/20 | 0.56 |
| ▸ | HCK | P08631 | 2/20 | 0.56 |
| ▸ | BCR | P11274 | 2/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | ABL2 | P42684 | 2/20 | 0.56 |
| ▸ | FRK | P42685 | 2/20 | 0.56 |
| ▸ | MST1R | Q04912 | 2/20 | 0.56 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.56 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12097157 | 0.90 | MET (0.65) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL2251761 | 0.89 | MET (0.69) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL2258237 | 0.87 | MET (0.72) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL1728382 | 0.86 | MET (0.76) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL1728635 | 0.86 | MET (0.67) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL1727517 | 0.86 | MET (0.69) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL2251542 | 0.86 | MET (0.73) | METKDRNTRK1TEKNTRK3 | |
| Hydrochloric Acid SCHEMBL1728468 | 0.85 | MET (0.75) | METKDRNTRK1TEKNTRK3 | |
| Bromide SCHEMBL4247685 | 0.85 | MET (0.75) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL143305 | 0.85 | MET (0.75) | METKDRNTRK1TEKNTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1889836-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | EISAI R&D MAN CO LTD (JP) | 2013-06-12 | — | — | EP | claimed |
| US-20120232049-A1 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-13 | — | — | US | claimed |
| US-7855290-B2 | N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; hepatocyte growth factor receptor (HGFR) inhibitors; antitumor, -carcinogenic, -metastasis agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-21 | — | — | US | claimed |
| EP-2119706-A1 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE | Eisai R&D Management Co., Ltd. (JP) | 2009-11-18 | — | — | EP | claimed |
| US-20090227556-A1 | RECEPTOR TYROSINE KINASE INHIBITORS COMPRISING PYRIDINE AND PYRIMIDINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | claimed |
| US-20090176797-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ESOPHAGEAL CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-09 | — | — | US | claimed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | claimed |
| EP-1889836-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | Eisai R&D Management Co., Ltd. (JP) | 2008-02-20 | — | — | EP | claimed |
| EP-1889836-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | EISAI R&D MAN CO LTD (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8288538-B2 | Pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288538-B2 | Pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288538-B2 | Pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120232049-A1 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232049-A1 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20090227556-A1 | RECEPTOR TYROSINE KINASE INHIBITORS COMPRISING PYRIDINE AND PYRIMIDINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090176797-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ESOPHAGEAL CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1889836-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | Eisai R&D Management Co., Ltd. (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227556-A1 | RECEPTOR TYROSINE KINASE INHIBITORS COMPRISING PYRIDINE AND PYRIMIDINE DERIVATIVES | RET, FLT1, KDR | MET 42/4885KDR 3/4885NTRK1 23/4885 |
| US-20090176797-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ESOPHAGEAL CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-10, H1-0 | MET 1876/4885KDR 4307/4885NTRK1 4436/4885 |
| US-20120232049-A1 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE | HGF, MET, MKI67 | MET 2/4885KDR 119/4885NTRK1 164/4885 |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | HGF, MET, FLT4 | MET 2/4885KDR 8/4885NTRK1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.